High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC)

Cancer Letters

Volumn 257, Issue 1, 2007, Pages 47-55

  Moreno, María ^a   Bontkes, Hetty J ^a   Scheper, Rik J ^a   Kenemans, Peter ^a   Verheijen, René H M ^a   von Mensdorff Pouilly, Silvia ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADCC; huHMFG 1 monoclonal antibody; MUC1; NK cells

Indexed keywords

AS 1402; CYTOKINE; FC RECEPTOR; HUMANIZED HUMAN MILK FAT GLOBULIN 1; MUCIN 1; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; DRUG EFFECT; DRUG INHIBITION; HUMAN; IN VITRO STUDY; NATURAL KILLER CELL; OVARY CANCER; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CELL LINE, TUMOR; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 34648820280     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.06.016     Document Type: Article

References (41)

1. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 5 (2004) 292-302
2. Arnould L., Gelly M., Penault-Llorca F., Benoit L., Bonnetain F., Migeon C., Cabaret V., Fermeaux V., Bertheau P., Garnier J., Jeannin J.F., and Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br. J. Cancer 94 (2006) 259-267
3. Banna G.L., Aversa S.M., Crivellari G., Ghiotto C., Chiarion-Sileni V., and Monfardini S. Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer. Br. J. Cancer 94 (2006) 1550-1552
4. Fischer L., Penack O., Gentilini C., Nogai A., Muessig A., Thiel E., and Uharek L. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp. Hematol. 34 (2006) 753-759
5. Ho S.B., Niehans G.A., Lyftogt C., Yan P.S., Cherwitz D.L., Gum E.T., Dahiya R., and Kim Y.S. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 53 (1993) 641-651
6. Karsten U., von Mensdorff-Pouilly S., and Goletz S. What makes MUC1 a tumor antigen?. Tumour Biol. 26 (2005) 217-220
7. Kotera Y., Fontenot J.D., Pecher G., Metzgar R.S., and Finn O.J. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 54 (1994) 2856-2860
8. von Mensdorff-Pouilly S., Snijdewint F.G., Verstraeten A.A., Verheijen R.H., and Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int. J. Biol. Markers 15 (2000) 343-356
9. Nakamura H., Hinoda Y., Nakagawa N., Makiguchi Y., Itoh F., Endo T., and Imai K. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J. Gastroenterol. 33 (1998) 354-361
10. Richards E.R., Devine P.L., Quin R.J., Fontenot J.D., Ward B.G., and McGuckin M.A. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol. Immunother. 46 (1998) 245-252
11. Hamanaka Y., Suehiro Y., Fukui M., Shikichi K., Imai K., and Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int. J. Cancer 103 (2003) 97-100
12. Hirasawa Y., Kohno N., Yokoyama A., Kondo K., Hiwada K., and Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 161 (2000) 589-594
13. von Mensdorff-Pouilly S., Gourevitch M.M., Kenemans P., Verstraeten A.A., Litvinov S.V., van Kamp G.J., Meijer S., Vermorken J., and Hilgers J. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur. J. Cancer 32A (1996) 1325-1331
14. von Mensdorff-Pouilly S., Verstraeten A.A., Kenemans P., Snijdewint F.G., Kok A., van Kamp G.J., Paul M.A., van Diest P.J., Meijer S., and Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol. 18 (2000) 574-583
15. Verhoeyen M.E., Saunders J.A., Price M.R., Marugg J.D., Briggs S., Broderick E.L., Eida S.J., Mooren A.T., and Badley R.A. Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody. Immunology 78 (1993) 364-370
16. Snijdewint F.G., von Mensdorff-Pouilly S., Karuntu-Wanamarta A.H., Verstraeten A.A., Livingston P.O., Hilgers J., and Kenemans P. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int. J. Cancer 93 (2001) 97-106
17. Bon G.G., von Mensdorff-Pouilly S., Kenemans P., van Kamp G.J., Verstraeten R.A., Hilgers J., Meijer S., and Vermorken J.B. Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clin. Chem. 43 (1997) 585-593
18. Kufe D., Inghirami G., Abe M., Hayes D., Justi-Wheeler H., and Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3 (1984) 223-232
19. Hilkens J., Buijs F., Hilgers J., Hageman P., Calafat J., Sonnenberg A., and van der Valk M. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int. J. Cancer 34 (1984) 197-206
20. Bon G.G., Kenemans P., Verstraeten R., van Kamp G.J., and Hilgers J. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am. J. Obstet. Gynecol. 174 (1996) 107-114
21. Engel L.W., Young N.A., Tralka T.S., Lippman M.E., O'Brien S.J., and Joyce M.J. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res. 38 (1978) 3352-3364
22. Leibson P.J. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 6 (1997) 655-661
23. Vance B.A., Huizinga T.W., Wardwell K., and Guyre P.M. Binding of monomeric human IgG defines an expression polymorphism of FcγRIII on large granular lymphocyte/natural killer cells. J. Immunol. 151 (1993) 6429-6439
24. Wu J., Edberg J.C., Redecha P.B., Bansal V., Guyre P.M., Coleman K., Salmon J.E., and Kimberly R.P. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100 (1997) 1059-1070
25. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., and Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
26. Pegram M.D., Borges V., Fuloria J., Ibrahim N., Shapiro C.L., Perez E.S., Wang K., Schaedeli Stark F., Yeon C., and Courtenay-Luck N. Phase I pharmacokinetics (PK) of humanized anti-MUC-1 antibody R1550. ASCO Meeting Abstracts 24 (2006) 2533
27. Koene H.R., Kleijer M., Algra J., Roos D., dem Borne A.E., and de Haas M. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood 90 (1997) 1109-1114
28. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., and Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
29. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., Watier H., and Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64 (2004) 4664-4669
30. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., and Presta L.G. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276 (2001) 6591-6604
31. Carson W.E., Parihar R., Lindemann M.J., Personeni N., Dierksheide J., Meropol N.J., Baselga J., and Caligiuri M.A. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur. J. Immunol. 31 (2001) 3016-3025
32. Choi B.S., Sondel P.M., Hank J.A., Schalch H., Gan J., King D.M., Kendra K., Mahvi D., Lee L.Y., Kim K., and Albertini M.R. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol. Immunother. 55 (2006) 761-774
33. Nguyen Q.H., Roberts R.L., Ank B.J., Lin S.J., Thomas E.K., and Stiehm E.R. Interleukin (IL)-15 enhances antibody-dependent cellular cytotoxicity and natural killer activity in neonatal cells. Cell. Immunol. 185 (1998) 83-92
34. Roda J.M., Parihar R., Lehman A., Mani A., Tridandapani S., and Carson III W.E. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J. Immunol. 177 (2006) 120-129
35. Fleming G.F., Meropol N.J., Rosner G.L., Hollis D.R., Carson W.E., Caligiuri M., Mortimer J., Tkaczuk K., Parihar R., Schilsky R.L., and Ratain M.J. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin. Cancer Res. 8 (2002) 3718-3727
36. Gluck W.L., Hurst D., Yuen A., Levine A.M., Dayton M.A., Gockerman J.P., Lucas J., Denis-Mize K., Tong B., Navis D., Difrancesco A., Milan S., Wilson S.E., and Wolin M. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res. 10 (2004) 2253-2264
37. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., and Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999) 727-729
38. Doubrovina E.S., Doubrovin M.M., Vider E., Sisson R.B., O'reilly R.J., Dupont B., and Vyas Y.M. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171 (2003) 6891-6899
39. Groh V., Wu J., Yee C., and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002) 734-738
40. Jinushi M., Takehara T., Tatsumi T., Hiramatsu N., Sakamori R., Yamaguchi S., and Hayashi N. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J. Hepatol. 43 (2005) 1013-1020
41. Wu J.D., Higgins L.M., Steinle A., Cosman D., Haugk K., and Plymate S.R. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 114 (2004) 560-568